Biomarkers for neurodegenerative disorders are essential to facilitate disease diagnosis,
ideally at early stages, monitor disease progression, and assess response to existing and …

Biomarker research is a rapidly advancing field in medicine. Recent advances in genomic,
genetic, epigenetic, neuroscientific, proteomic, and metabolomic knowledge and …

Dementias are prevalent brain disorders in the aged population. Dementias pose major
socio‐medical burden, but currently there is no cure available. Novel proteomics …

The technology, experimental approaches, and bioinformatics that support proteomic
research are evolving rapidly. The application of these new capabilities to the study of …

Neurodegenerative disorders are characterized by neuronal impairment that eventually
leads to neuronal death. In spite of the brain's known capacity for regeneration, lost neurons …

The clinical diagnosis of major neurodegenerative disorders, eg Alzheimer's disease,
Parkinson's disease, and dementia with Lewy body, remains unsatisfactory based on current …

Biomarker research for Alzheimer's disease (AD) has been growing rapidly over recent
years especially as the number of persons affected by this disease is nearing approximately …

The development of MALDI ESI in the late 1980s has revolutionized the biological sciences
and facilitated the emergence of a new discipline called proteomics. Application of …

Proteins as a product from genetic information execute and determine how development,
growth, aging and disease factors are orchestrated within the lifetime of an organism …

The understanding of neurodegenerative diseases, traditionally considered to be well-
defined entities with distinguishable clinical phenotypes, has undergone a major shift over …